INTRODUCTION: We as Anaesthesiologists are always worried about the occurrence of recurrent Ischemic attacks and irreversible Bronchospasm
during General Anaesthesia which can lead to high mortality rates.
The Spiriva HandiHaler (Boehringer Ingelheim/Pfizer) was approved in 2004 for the long-term maintenance treatment of bronchospasm
associated with COPD, including chronic bronchitis and emphysema.
The Spiriva HandiHaler, marketed by Boehringer Ingelheim and Pfizer, was approved in 2004 for the long-term maintenance treatment of bronchospasm
associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
The Food and Drug Administration has issued a public health advisory emphasizing the potentially lethal risk of bronchospasm
in children using any of three brands of bronchodilators, as noted in two of the drugs' new medication guides and in warnings added in March to those drugs' labels.
For that reason, we recommend routine pulse oximetry at baseline and during and after the use of restraints in case of postrestraint bronchospasm
Manufactured by Novartis Pharmaceuticals Corp., Brethine is marketed for the prevention and reversal of bronchospasm
. The product had sales of approximately $15 million in the U.S.
In addition to bronchospasm
and increased mucous production, there is a battle raging in the lung.
as a consequence of PPDA is usually seen in hairdressers, who are constantly exposed to PPDA.
Isoproterenol Hydrochloride Injection USP is indicated for mild or transient episodes of heart block, for serious episodes of heart block and Adams-Stokes attacks, use in cardiac arrest until electric shock or pacemaker therapy, bronchospasm
occurring during anesthesia, as an adjunct to fluid and electrolyte replacement therapy as well as in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure and cardiogenic shock, concluded the company.
Its side-effects include elevation of heart rate and blood pressure, anxiety, manic reactions and bronchospasm
. Products containing yohimbine can only be sold in a pharmacy under the supervision of a registered pharmacist.
The dry-powder formulation of tiotropium, marketed as the Spiriva Handi-Haler by Boehringer Ingelheim and Pfizer, was approved in the United States in 2004 for long-term maintenance treatment of bronchospasm
associated with chronic obstructive pulmonary disorder, including chronic bronchitis and emphysema.
The FDA approved Spiriva in 2004 for the long-term treatment of bronchospasm
associated with COPD.